Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway

Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysis

(2016) Mahiben Maruthappu et al.   LANCET

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy

(2015) Danila Coradini et al.   BREAST

Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation

(2014) Marja Moerkens et al.   BMC CANCER

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer

(2012) Tiantian Cui et al.   CARCINOGENESIS

p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation

(2011) S. Huang et al.   CANCER RESEARCH

Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy

(2011) F. Wei et al.   CURRENT MEDICINAL CHEMISTRY

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

(2011) L. Mollgard et al.   HAEMATOLOGICA

Correlation of Cellular Immunity With Human Papillomavirus 16 Status and Outcome in Patients With Advanced Oropharyngeal Cancer

(2010) Derrick Wansom et al.   ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY

Role of Epidermal Growth Factor Receptor Degradation in Cisplatin-Induced Cytotoxicity in Head and Neck Cancer

(2010) Aarif Ahsan et al.   CANCER RESEARCH

Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers

(2010) J. Lehmann-Che et al.   ONCOLOGIST

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

(2009) A Oden-Gangloff et al.   BRITISH JOURNAL OF CANCER

DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: Role of E-cadherin

(2009) Manuel Rieber et al.   INTERNATIONAL JOURNAL OF CANCER

Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway

(2009) Peixin Dong et al.   Molecular Cancer

MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma

(2009) F. Marampon et al.   MOLECULAR CANCER THERAPEUTICS

Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells

(2008) Kwang-Kyu Kim et al.   CARCINOGENESIS

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells

(2008) J.-C. Ko et al.   CARCINOGENESIS

Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)

(2008) Ankur Upadhyay et al.   CURRENT CANCER DRUG TARGETS